Outsourcing Outlook

Preferred models for clinical and nonclinical services move in opposite directions.

Preferred models for clinical and nonclinical services move in opposite directions.

Strong demand is straining service providers' project-management capabilities; Patheon receives a much-needed cash infusion.

Strong demand is straining service providers' project-management capabilities; Patheon receives a much-needed cash infusion.

As big pharmaceutical companies restructure and reevaluate the way they do business, contract research and manufacturing organizations could reap greater financial rewards.

As big pharmaceutical companies restructure and reevaluate the way they do business, contract research and manufacturing organizations could reap greater financial rewards.

Sixty deals were completed in 2006, with a total value of $2 billion.

Sixty deals were completed in 2006, with a total value of $2 billion.

The recent struggles of Cardinal Health's and Patheon's contract dose manufacturing businesses offer a lesson on good business practices.

The recent struggles of Cardinal Health's and Patheon's contract dose manufacturing businesses offer a lesson on good business practices.

The recent struggles of Cardinal Health's and Patheon's contract dose manufacturing businesses offer a lesson on good business practices.

The integrated services model is the "next big thing" in CMC and early development services.

The integrated services model is the "next big thing" in CMC and early development services.

Mid-size regional players have little chance for success in an industry increasingly dominated by large global players.

Mid-size regional players have little chance for success in an industry increasingly dominated by large global players.

More CMOs look to proprietary delivery technologies to enhance profitability.

More CMOs look to proprietary delivery technologies to enhance profitability.

More CMOs look to proprietary delivery technologies to enhance profitability.

Contract service providers should be concerned about the market perceptions of their performance.

Contract service providers should be concerned about the market perceptions of their performance.

The principal objective of the annual PharmSource–Pharmaceutical Technology outsourcing survey is to gauge overall business trends in the contract manufacturing and research businesses. This year's edition documents an industry that is in good health but facing a new set of dynamics.

China is on the rise as a center for pharmaceutical R&D, but companies are still getting their footing for operating in China and the services industry has some maturing to do.

China is on the rise as a center for pharmaceutical R&D, but companies are still getting their footing for operating in China and the services industry has some maturing to do.

The laboratory supplier landscape is undergoing a radical makeover.

Buyers strategically target chemistry, manufacturing, and controls development services.

Recent deals suggest companies are willing to pay up to get into CMC services.

Pharmaceutical companies are seeing the development process in a new way, and that has major implications for service providers.

CMOs face market realities and exit some businesses.

The big question for pharmaceutical services providers coming into 2006 is: will the good times continue to roll?

CROs and CMOs are pursuing new strategies to win a larger share of the burgeoning early development pipeline.